CD274 and melanoma: Studies have shown that various malignancies are groundbreaking in this regard (6); for example, blocking programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoints can modify the prognosis of non-small cell lung cancer (NSCLC), gastric cancer, head and neck squamous cell carcinoma, and melanoma to some extent (7–11).